Results 231 to 240 of about 92,540 (302)

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon   +11 more
wiley   +1 more source

Analysis of clinical investigation (device) initial submissions received by the Medicines and Healthcare products Regulatory Agency between January 2022 and December 2025

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse clinical investigation‐device initial submissions received by the MHRA between January 2022 and December 2025. Methods Data on submissions were extracted from the clinical investigations unit data bank; software as medical devices were not included. The predefined primary end‐point was submission type.
Andrea Manfrin   +7 more
wiley   +1 more source

Place Dressing

open access: yescraft + design enquiry, 2015
openaire   +2 more sources

Effectiveness of negative pressure wound therapy versus conventional dressings in emergency laparotomy: a systematic review and meta-analysis of randomized controlled trials. [PDF]

open access: yesArq Bras Cir Dig
Antonini FS   +12 more
europepmc   +1 more source

Therapeutic potential of herbal topical agents in evidence-based wound care: a systematic research review. [PDF]

open access: yes3 Biotech
Kumari R   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy